Author:
Abdelbaky Ibrahim,Tayara Hilal,Chong Kil To
Abstract
AbstractProtein kinases are receiving wide research interest, from drug perspective, due to their important roles in human body. Available kinase-inhibitor data, including crystallized structures, revealed many details about the mechanism of inhibition and binding modes. The understanding and analysis of these binding modes are expected to support the discovery of kinase-targeting drugs. The huge amounts of data made it possible to utilize computational techniques, including machine learning, to help in the discovery of kinase-targeting drugs. Machine learning gave reasonable predictions when applied to differentiate between the binding modes of kinase inhibitors, promoting a wider application in that domain. In this study, we applied machine learning supported by feature selection techniques to classify kinase inhibitors according to their binding modes. We represented inhibitors as a large number of molecular descriptors, as features, and systematically reduced these features in a multi-step manner while trying to attain high classification accuracy. Our predictive models could satisfy both goals by achieving high accuracy while utilizing at most 5% of the modeling features. The models could differentiate between binding mode types with MCC values between 0.67 and 0.92, and balanced accuracy values between 0.78 and 0.97 for independent test sets.
Funder
National Research Foundation of Korea
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Sacco, F., Perfetto, L., Castagnoli, L. & Cesareni, G. The human phosphatase interactome: an intricate family portrait. FEBS Lett. 586, 2732–2739 (2012).
2. Ardito, F., Giuliani, M., Perrone, D. & Troiano, G. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy. Int. J. Mol. Med. 40, 271–280 (2017).
3. Abdelbaky, I. Z., Al-Sadek, A. F. & Badr, A. A. Applying machine learning techniques for classifying cyclin-dependent kinase inhibitors. Int. J. Adv. Comput. Sci. Appl. 9, 229–235 (2018).
4. Roskoski, R. Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol. Res. 100, 1–23 (2015).
5. Roskoski, R. Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol. Res. 152, 104609 (2020).
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献